AB-001 / Aubrak Therapeutics - LARVOL DELTA

Phase 1/2 Dose Escalation and Expansion of AB001 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC): The ARTISAN Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Combination of PSMA targeting alpha-emitting radioligand [212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models. (PubMed, Med Oncol) - "Bromodomain and extra-terminal (BET) protein inhibitors, such as AZD5153 and JQ1, disrupt oncogenic transcriptional programs by altering chromatin structure. In 3D spheroids, combination treatment led to synergistic growth suppression. In conclusion, these findings indicate that therapeutic inhibition of BET bromodomain in combination with the alpha-emitting radioligand [212Pb]Pb-AB001 could significantly enhance tumour control and should be further evaluated in metastatic prostate cancer models."

Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer. (PubMed, Eur J Nucl Med Mol Imaging) - "[212Pb]Pb-AB001 showed significant efficacy against micrometastases and advantages over [177Lu]Lu-PSMA-617 in preventing or treating early bone metastases for the investigated injected activities. This implies clinical potential for treating mCRPC, including patients at risk of early metastatic disease, but further studies including dosimetry and toxicity analyses are required with regards to activity levels."

Journal • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

INTERIM RESULTS FROM THE PHASE I IBC -01-01 STUDY: THE FIRST IMMUNE CHECKPOINT INHIBITOR THERAPY IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE (ADPD 2025) - "IBC -01-01 is a Phase I clinical study investigating the safety, tolerability, and preliminary efficacy of IBC -Ab001, a no vel immunomodulatory agent designed to harness peripheral immunity by targeting the inhibitory immune checkpoint PD -L1 in patients with early AD. IBC-01-01 adopts an innovative approach in AD treatment by targeting an immune checkpoint inhibitor for the fir st time in dementia therapy. This first -of-its-kind treatment represents a unique approach to targeting AD by leveraging the physiological role of the immune system in brain repair."

Checkpoint inhibition • Clinical • IO biomarker • P1 data • Alzheimer's Disease • CNS Disorders • Dementia • Inflammation • Oncology • APOE

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer. (PubMed, J Nucl Med) - "γ-camera imaging of AB001 was feasible, even at a microdose, and demonstrated metastatic targeting, albeit for only 1 lesion. The promising biodistribution and clearance encourage further clinical investigation."

Journal • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1